AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 6, 2023
Missling is being "patient" taking month... See more
Jan, 6, 2023
Abrahams sees ultimate approval as "very like... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Feb, 21, 2023
$TGTX next few weeks will be a good buying opportu... See more
Jan, 16, 2023
$TGTX "4 Stories of Living with Multiple Scle... See more
OUST
Ouster Inc - Ordinary Shares - Class A
-49.79%
$1.74 - $0.87
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
$OUST "Our sensor-agnostic solutions provide... See more
Jan, 24, 2023
"Digital lidar never stops improving – and do... See more
Jan, 6, 2023
Missling is being "patient" taking months longer than any other company to analyze and release trial data (and then not actually releasing the full data set), so he's awesome.
Jan, 6, 2023
Abrahams sees ultimate approval as "very likely" and a favorable setup in Biogen shares.
Dec, 9, 2022
$AVXL George Perry stated, the Anavex drug is "revolutionary", as is uniquely good, no other drug has EVER increased cognition EVER.
Dec, 7, 2022
IMO, with their "rapid" label and test showing sustained improvement in cognition and daily living, it will be hard not to try Auvelity if you suffer from MDD.
Dec, 6, 2022
Value is what you get. "Revolutionary."
Dec, 6, 2022
The results are incredible and 50mg study with no side effects is spectacular."
Dec, 5, 2022
The information points clearly this is much better than "Aduhelm" or Lecanemab.
Feb, 21, 2023
$TGTX next few weeks will be a good buying opportunity for "risk on" assets imo.
Jan, 16, 2023
$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 26, 2022
Check it out below.""" 👇 Highly recommend everyone to follow them 💪 https://amazing-stocks-us.stockmarketus.net/